Cardiovascular Outcomes of PCSK9 Inhibitors: With Special Emphasis on Its Effect beyond LDL-Cholesterol Lowering

PCSK9 inhibitors, monoclonal antibodies, are novel antihypercholesterolemic drugs. FDA first approved them in July 2015. PCSK9 protein (692-amino acids) was discovered in 2003. It plays a major role in LDL receptor degradation and is a prominent modulator in low-density lipoprotein cholesterol (LDL-...

Descripción completa

Detalles Bibliográficos
Autores principales: Bandyopadhyay, Dhrubajyoti, Ashish, Kumar, Hajra, Adrija, Qureshi, Arshna, Ghosh, Raktim K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5889852/
https://www.ncbi.nlm.nih.gov/pubmed/29770231
http://dx.doi.org/10.1155/2018/3179201

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5889852/
https://www.ncbi.nlm.nih.gov/pubmed/29770231
http://dx.doi.org/10.1155/2018/3179201

Ejemplares similares